Cost Of AstraZeneca's Break-Up With Merck On Track To Be $3.3 Bil.
This article was originally published in The Pink Sheet Daily
Joint venture exit will allow AstraZeneca more freedom to in-license products, executives say.
You may also be interested in...
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.
US vaccination campaign will pick up speed now that access is broadening, leaders from Operation Warp Speed, Pfizer, Moderna, McKesson and CVS Health say at a J.P. Morgan panel discussion.